[go: up one dir, main page]

CA3015642A1 - Systeme de transposon et procedes d'utilisation - Google Patents

Systeme de transposon et procedes d'utilisation Download PDF

Info

Publication number
CA3015642A1
CA3015642A1 CA3015642A CA3015642A CA3015642A1 CA 3015642 A1 CA3015642 A1 CA 3015642A1 CA 3015642 A CA3015642 A CA 3015642A CA 3015642 A CA3015642 A CA 3015642A CA 3015642 A1 CA3015642 A1 CA 3015642A1
Authority
CA
Canada
Prior art keywords
sequence encoding
dna sequence
transposon
amount
electroporation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3015642A
Other languages
English (en)
Inventor
Devon SHEDLOCK
David Hermanson
Eric Ostertag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poseida Therapeutics Inc
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of CA3015642A1 publication Critical patent/CA3015642A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés de modification génétique ex-vivo d'une cellule immunitaire consistant à administrer à la cellule immunitaire, (a) une séquence d'acides aminés ou d'acide nucléique comprenant une séquence codant pour une enzyme transposase et b) une séquence d'ADN non naturelle et recombinante comprenant une séquence d'ADN codant pour un transposon.
CA3015642A 2016-02-26 2017-02-24 Systeme de transposon et procedes d'utilisation Abandoned CA3015642A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300387P 2016-02-26 2016-02-26
US62/300,387 2016-02-26
PCT/US2017/019531 WO2017147538A1 (fr) 2016-02-26 2017-02-24 Système de transposon et procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA3015642A1 true CA3015642A1 (fr) 2017-08-31

Family

ID=58314517

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015642A Abandoned CA3015642A1 (fr) 2016-02-26 2017-02-24 Systeme de transposon et procedes d'utilisation

Country Status (12)

Country Link
EP (1) EP3420090A1 (fr)
JP (1) JP2019506177A (fr)
KR (1) KR20180131545A (fr)
CN (1) CN109312361A (fr)
AU (1) AU2017224111A1 (fr)
BR (1) BR112018067536A2 (fr)
CA (1) CA3015642A1 (fr)
IL (1) IL261343A (fr)
MX (1) MX2018010288A (fr)
RU (1) RU2018133691A (fr)
SG (1) SG11201807134RA (fr)
WO (1) WO2017147538A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494132A4 (fr) 2016-08-03 2020-03-18 Washington University Édition génétique des cellules car-t pour le traitement de malignités des lymphocytes t avec des récepteurs d'antigènes chimériques
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
IL267334B2 (en) 2016-12-16 2025-01-01 B Mogen Biotechnologies Inc Enhanced gene transfer mediated by the hAT transposon family and related compositions, systems and methods
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变系统及构建方法
WO2019046815A1 (fr) * 2017-08-31 2019-03-07 Poseida Therapeutics, Inc. Système de transposon et procédés d'utilisation
US12385061B2 (en) 2017-09-08 2025-08-12 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
EP3810764A2 (fr) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Transfert amélioré de gènes médié par transposon de la famille hat et compositions, systèmes et méthodes associés
SG11202108665PA (en) * 2019-02-08 2021-09-29 Dna Twopointo Inc Transposon-based modifications of immune cells
CN111926041B (zh) * 2020-10-16 2020-12-25 广州吉妮欧生物科技有限公司 一种SARS-CoV-2假病毒小鼠体内包装系统及其制备方法
CN114246986B (zh) * 2021-12-29 2022-08-23 中国人民解放军陆军军医大学 一种基于原位调控免疫反应的心血管植入物及其制备方法
CN118185901B (zh) * 2022-12-12 2025-03-21 北京精缮生物科技有限责任公司 一种PBase蛋白、融合蛋白、核酸和基因整合系统及应用
CN116590341A (zh) * 2023-07-13 2023-08-15 山东维真生物科技有限公司 一种腺病毒-PiggyBac系统及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
WO2010099301A2 (fr) * 2009-02-25 2010-09-02 The Johns Hopkins University Variants de transposon piggybac et procédés d'utilisation
US8399643B2 (en) * 2009-02-26 2013-03-19 Transposagen Biopharmaceuticals, Inc. Nucleic acids encoding hyperactive PiggyBac transposases
US20130045491A1 (en) * 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
WO2014077863A1 (fr) * 2012-11-19 2014-05-22 Nature Technology Corporation Vecteurs réplicatifs en minicercle avec une expression améliorée

Also Published As

Publication number Publication date
BR112018067536A2 (pt) 2019-02-05
SG11201807134RA (en) 2018-09-27
EP3420090A1 (fr) 2019-01-02
JP2019506177A (ja) 2019-03-07
CN109312361A (zh) 2019-02-05
AU2017224111A1 (en) 2018-09-13
IL261343A (en) 2018-10-31
MX2018010288A (es) 2019-06-06
RU2018133691A3 (fr) 2020-07-29
RU2018133691A (ru) 2020-03-26
WO2017147538A1 (fr) 2017-08-31
KR20180131545A (ko) 2018-12-10

Similar Documents

Publication Publication Date Title
CA3015642A1 (fr) Systeme de transposon et procedes d'utilisation
KR102708285B1 (ko) 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법
JP6965466B2 (ja) 操作されたカスケード構成要素およびカスケード複合体
US11952408B2 (en) HPV-specific binding molecules
KR102588469B1 (ko) 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법
US20190241910A1 (en) Genome edited immune effector cells
CA3111384A1 (fr) Compositions de cellules allogeniques et methodes d'utilisation
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
KR102810368B1 (ko) 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
CA3086187A1 (fr) Compositions de vcar et methodes d'utilisation
CN108601821A (zh) 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
JP2018536390A (ja) ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
AU2016373365B2 (en) Transposon system, kit comprising the same, and uses thereof
EP3720453B1 (fr) Lymphocytes modifiés
US20240000969A1 (en) Compositions and methods for delivery of nucleic acids
US20190233843A1 (en) Transposon system and methods of use
CN114630909A (zh) 环状rna、包含环状rna的疫苗及用于检测新型冠状病毒中和抗体的试剂盒
JP2022547866A (ja) 同種異系細胞組成物と使用方法
RU2561466C2 (ru) Плазмида для экспрессии рекомбинантного фактора свертываемости крови viii человека с делетированным в-доменом в клетках сно, клетка сно - продуцент рекомбинантного фактора свертываемости крови viii человека с делетированным в-доменом и способ получения указанного фактора
RU2792187C2 (ru) Композиции cart-иринов и способы их применения
US20260034241A1 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
WO2024050551A2 (fr) Compositions et procédés d'expression in vivo de récepteurs antigéniques chimériques
JP2025542097A (ja) 抗ａｆｐ／ｈｌａ０２ ｔｃｒ様抗体及びその使用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230524